About: Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.87 (+2.65%)
MSLENASDAQSatellos Bioscience Inc. Common Stock
Loading watchlist status…
Satellos Bioscience Inc. Common Stock share price
MSLE price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
MSLE price performance
-1.45%
5D
10.22%
1M
-15.12%
YTD
-15.12%
1Y
MSLE price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US-NASDAQ rank
N/ASector Rank
N/AMSLE details
MSLE Market Signals